DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.

Protein-protein interactions represent an exciting and challenging target class for therapeutic intervention using small molecules. Protein interaction sites are often devoid of the deep surface pockets presented by "traditional" drug targets, and crystal structures reveal that inhibitors typically engage these sites using very shallow binding modes. As a consequence, modern virtual screening tools developed to identify inhibitors of traditional drug targets do not perform as well when they are instead deployed at protein interaction sites. To address the need for novel inhibitors of important protein interactions, here we introduce an alternate docking strategy specifically designed for this regime. Our method, termed DARC (Docking Approach using Ray-Casting), matches the topography of a surface pocket "observed" from within the protein to the topography "observed" when viewing a potential ligand from the same vantage point. We applied DARC to carry out a virtual screen against the protein interaction site of human antiapoptotic protein Mcl-1 and found that four of the top-scoring 21 compounds showed clear inhibition in a biochemical assay. The Ki values for these compounds ranged from 1.2 to 21 μM, and each had ligand efficiency comparable to promising small-molecule inhibitors of other protein-protein interactions. These hit compounds do not resemble the natural (protein) binding partner of Mcl-1, nor do they resemble any known inhibitors of Mcl-1. Our results thus demonstrate the utility of DARC for identifying novel inhibitors of protein-protein interactions.

[1]  Brian K Shoichet,et al.  Interpreting steep dose-response curves in early inhibitor discovery. , 2006, Journal of medicinal chemistry.

[2]  Thomas Lengauer,et al.  FlexE: efficient molecular docking considering protein structure variations. , 2001, Journal of molecular biology.

[3]  Emiko Fire,et al.  The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer , 2010, Nature chemical biology.

[4]  Hui Sun Lee,et al.  Improving Virtual Screening Performance against Conformational Variations of Receptors by Shape Matching with Ligand Binding Pocket , 2009, J. Chem. Inf. Model..

[5]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[6]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.

[7]  Yuta Tanaka,et al.  Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. , 2013, Journal of medicinal chemistry.

[8]  Sergey Lyskov,et al.  DARC 2.0: Improved Docking and Virtual Screening at Protein Interaction Sites , 2015, PloS one.

[9]  Weifan Zheng,et al.  Novel Approach to Structure-Based Pharmacophore Search Using Computational Geometry and Shape Matching Techniques , 2008, J. Chem. Inf. Model..

[10]  Chang Park,et al.  Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein. , 2014, Bioorganic & medicinal chemistry letters.

[11]  Rommie E. Amaro,et al.  Ensemble-Based Virtual Screening Reveals Potential Novel Antiviral Compounds for Avian Influenza Neuraminidase , 2008, Journal of medicinal chemistry.

[12]  Woody Sherman,et al.  Exploring protein flexibility: incorporating structural ensembles from crystal structures and simulation into virtual screening protocols. , 2012, The journal of physical chemistry. B.

[13]  D. Kihara,et al.  Real‐time ligand binding pocket database search using local surface descriptors , 2010, Proteins.

[14]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[15]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[16]  E. Katchalski‐Katzir,et al.  Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Eric J. Deeds,et al.  Structural Properties of Non-Traditional Drug Targets Present New Challenges for Virtual Screening , 2013, J. Chem. Inf. Model..

[18]  Anthony Nicholls,et al.  What do we know and when do we know it? , 2008, J. Comput. Aided Mol. Des..

[19]  G. Wei,et al.  Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1). , 2014, ACS medicinal chemistry letters.

[20]  X. Zou,et al.  Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking , 2006, Proteins.

[21]  Kunal Roy,et al.  How far can virtual screening take us in drug discovery? , 2013, Expert opinion on drug discovery.

[22]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[23]  R. Nolen 'Between a rock and a hard place'. , 2002, Journal of the American Veterinary Medical Association.

[24]  I. Kuntz,et al.  DOCK 6: combining techniques to model RNA-small molecule complexes. , 2009, RNA.

[25]  David Ryan Koes,et al.  Small-molecule inhibitor starting points learned from protein–protein interaction inhibitor structure , 2011, Bioinform..

[26]  David S. Goodsell,et al.  Protein Flexibility in Virtual Screening: The BACE-1 Case Study , 2012, J. Chem. Inf. Model..

[27]  R. Desimone,et al.  Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.

[28]  D. Fabbro,et al.  Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate. , 2014, Methods in enzymology.

[29]  M. Pellecchia,et al.  SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1. , 2011, Journal of medicinal chemistry.

[30]  Brian A. Chauder,et al.  Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. , 2013, Journal of medicinal chemistry.

[31]  G. Petsko,et al.  Multiple solvent crystal structures: probing binding sites, plasticity and hydration. , 2006, Journal of molecular biology.

[32]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[33]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[34]  Alexander Dömling,et al.  Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? , 2008, Current opinion in chemical biology.

[35]  Kristin E. D. Coan,et al.  Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding , 2009, Journal of medicinal chemistry.

[36]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[37]  Dustin J Maly,et al.  Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. , 2013, ACS chemical biology.

[38]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[39]  Eric B Fauman,et al.  Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics. , 2011, Current opinion in chemical biology.

[40]  Scott A. Erickson,et al.  Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. , 2015, Journal of medicinal chemistry.

[41]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[42]  Sudipto Mukherjee,et al.  Evaluation of DOCK 6 as a pose generation and database enrichment tool , 2012, Journal of Computer-Aided Molecular Design.

[43]  Jean-Philippe Vert,et al.  A new protein binding pocket similarity measure based on comparison of clouds of atoms in 3D: application to ligand prediction , 2010, BMC Bioinformatics.

[44]  Gennady Verkhivker,et al.  Integrating Ligand-Based and Protein-Centric Virtual Screening of Kinase Inhibitors Using Ensembles of Multiple Protein Kinase Genes and Conformations , 2012, J. Chem. Inf. Model..

[45]  Wang Shen,et al.  A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. , 2006, Cancer research.

[46]  P Willett,et al.  Similarity-based approaches to virtual screening. , 2003, Biochemical Society transactions.

[47]  Kalle Gehring,et al.  The discovery of small molecule chemical probes of Bcl-X(L) and Mcl-1. , 2008, Bioorganic & medicinal chemistry.

[48]  K. Jacobson Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. , 2013, Journal of medicinal chemistry.

[49]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[50]  Jolanta Grembecka,et al.  Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? , 2015, Immunological reviews.

[51]  C. Lemmen,et al.  FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.

[52]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[53]  Tao Zhang,et al.  A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[54]  Gaohua Liu,et al.  High-Quality NMR Structure of Human Anti-Apoptotic Protein Domain Mcl-1(171-327) for Cancer Drug Design , 2014, PloS one.

[55]  Ruth Nussinov,et al.  PatchDock and SymmDock: servers for rigid and symmetric docking , 2005, Nucleic Acids Res..

[56]  Bin Li,et al.  Characterization of local geometry of protein surfaces with the visibility criterion , 2008, Proteins.

[57]  S. Knapp,et al.  A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics , 2014, Nature chemical biology.

[58]  Hong-Gang Wang,et al.  Synthesis of cell-permeable stapled BH3 peptide-based Mcl-1 inhibitors containing simple aryl and vinylaryl cross-linkers. , 2014, Tetrahedron.

[59]  B. Srinivasan,et al.  Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities. , 2009, Journal of medicinal chemistry.

[60]  Anthony Nicholls,et al.  Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures , 2012, J. Chem. Inf. Model..

[61]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[62]  H. Carlson,et al.  An Allosteric Modulator of HIV-1 Protease Shows Equipotent Inhibition of Wild-Type and Drug-Resistant Proteases , 2014, Journal of medicinal chemistry.

[63]  Holger Gohlke,et al.  From Determinants of RUNX1/ETO Tetramerization to Small-Molecule Protein-Protein Interaction Inhibitors Targeting Acute Myeloid Leukemia , 2013, J. Chem. Inf. Model..

[64]  Alexander D. MacKerell,et al.  The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein–protein interactions with Bak , 2013, Molecular Cancer.

[65]  Olivier Sperandio,et al.  How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis , 2010, European Biophysics Journal.

[66]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[67]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[68]  Grzegorz M. Popowicz,et al.  Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists , 2012, PloS one.

[69]  Matthew E Welsch,et al.  Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.

[70]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[71]  M. Sternberg,et al.  Modelling protein docking using shape complementarity, electrostatics and biochemical information. , 1997, Journal of molecular biology.

[72]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[73]  H. Abaan,et al.  Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.

[74]  M. Butterworth,et al.  Evaluation and critical assessment of putative MCL-1 inhibitors , 2013, Cell Death and Differentiation.

[75]  Hong-Gang Wang,et al.  Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. , 2012, Journal of the American Chemical Society.

[76]  David K. Johnson,et al.  Selectivity by Small-Molecule Inhibitors of Protein Interactions Can Be Driven by Protein Surface Fluctuations , 2015, PLoS Comput. Biol..

[77]  Janet M. Thornton,et al.  Real spherical harmonic expansion coefficients as 3D shape descriptors for protein binding pocket and ligand comparisons , 2005, Bioinform..

[78]  Robert V. Swift,et al.  Molecular docking to flexible targets. , 2015, Methods in molecular biology.

[79]  Landon R. Whitby,et al.  Comprehensive peptidomimetic libraries targeting protein-protein interactions. , 2012, Accounts of chemical research.

[80]  Oliver Korb,et al.  Potential and Limitations of Ensemble Docking , 2012, J. Chem. Inf. Model..

[81]  S. Sebti,et al.  The BH3 α-Helical Mimic BH3-M6 Disrupts Bcl-XL, Bcl-2, and MCL-1 Protein-Protein Interactions with Bax, Bak, Bad, or Bim and Induces Apoptosis in a Bax- and Bim-dependent Manner* , 2010, The Journal of Biological Chemistry.

[82]  S. Fesik,et al.  Small molecule Mcl-1 inhibitors for the treatment of cancer. , 2015, Pharmacology & therapeutics.

[83]  S. Fesik,et al.  Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. , 2013, Journal of medicinal chemistry.

[84]  Yinliang Yang,et al.  Target profiling of 4-hydroxyderricin in S. aureus reveals seryl-tRNA synthetase binding and inhibition by covalent modification. , 2013, Molecular bioSystems.

[85]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[86]  M. Soengas,et al.  Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins , 2007, Cell Death and Differentiation.

[87]  Xueguang Shao,et al.  Protein-ligand recognition using spherical harmonic molecular surfaces: towards a fast and efficient filter for large virtual throughput screening. , 2002, Journal of molecular graphics & modelling.

[88]  Renaldo Mendoza,et al.  Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. , 2010, Bioorganic & medicinal chemistry letters.

[89]  S. Amslinger,et al.  Reactivity assessment of chalcones by a kinetic thiol assay. , 2013, Organic & biomolecular chemistry.

[90]  Tom L. Blundell,et al.  TIMBAL v2: update of a database holding small molecules modulating protein–protein interactions , 2013, Database J. Biol. Databases Curation.

[91]  Jonathan H. Sheehan,et al.  Tailoring Peptidomimetics for Targeting Protein–Protein Interactions , 2014, Molecular Cancer Research.

[92]  T. Blundell,et al.  Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.

[93]  T. Cihlar,et al.  Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. , 2010, Antiviral research.

[94]  M Hendlich,et al.  LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. , 1997, Journal of molecular graphics & modelling.

[95]  Jens Meiler,et al.  ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. , 2011, Methods in enzymology.

[96]  Xavier Barril,et al.  rDock: A Fast, Versatile and Open Source Program for Docking Ligands to Proteins and Nucleic Acids , 2014, PLoS Comput. Biol..

[97]  C. Chung,et al.  Effect of detergent on "promiscuous" inhibitors. , 2003, Journal of medicinal chemistry.

[98]  Z. Nikolovska-Coleska,et al.  Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review , 2012, Expert opinion on therapeutic patents.

[99]  David R. W. Hodgson,et al.  Chemical approaches towards unravelling kinase-mediated signalling pathways. , 2011, Chemical Society reviews.

[100]  Xiao Ding,et al.  De Novo Design, Synthesis and Evaluation of Benzylpiperazine Derivatives as Highly Selective Binders of Mcl‐1 , 2013, ChemMedChem.

[101]  A. Hamilton,et al.  Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. , 2010, Current opinion in chemical biology.

[102]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[103]  Alicia P. Higueruelo,et al.  Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database , 2009, Chemical biology & drug design.

[104]  Paul N. Mortenson,et al.  Diverse, high-quality test set for the validation of protein-ligand docking performance. , 2007, Journal of medicinal chemistry.

[105]  B. Shoichet,et al.  Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. , 2003, Journal of medicinal chemistry.

[106]  Olivier Sperandio,et al.  Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. , 2014, Journal of medicinal chemistry.

[107]  Alexander M. Lewis,et al.  Identification of a chemical probe for NAADP by virtual screening , 2009, Nature chemical biology.

[108]  T. Chambers,et al.  Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines , 2013, Cell Death and Disease.

[109]  Ramaswamy Nilakantan,et al.  Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. , 2006, Bioorganic & medicinal chemistry.

[110]  Emiko Fire,et al.  Mcl‐1–Bim complexes accommodate surprising point mutations via minor structural changes , 2010, Protein science : a publication of the Protein Society.

[111]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[112]  David K. Johnson,et al.  Druggable Protein Interaction Sites Are More Predisposed to Surface Pocket Formation than the Rest of the Protein Surface , 2013, PLoS Comput. Biol..

[113]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[114]  Karen R. Khar,et al.  Fast Docking on Graphics Processing Units via Ray-Casting , 2013, PloS one.